Asian casinos and airlines rose sharply after Pfizer stated that her tablet from coronavirus could reduce the number of hospitalizations and deaths among patients by 89 percent, Bloomberg reports.
Casino shares in Macau increased in price by 5.9 percent, demonstrating the greatest growth over the past two months, while the index of shares of the Airlines of the Asia-Pacific region increased by 4.5 percent – this is the maximum from March. Shares of the manufacturer of suitcases and travel bags Samsonite rose by 14 percent. Grow out in the price and shares of American airlines. On November 5, the Shares of Delta Air Lines went up by 8.05 percent, United Airlines – 7.26 percent, Southwest Airlines – by 6.44 percent, American Airlines – by 5.77 percent, according to NASDAQ Exchange.
Although Pfizer tablets have not yet received permits from US regulators, investors believe that the drug will help in the fight against the pandemic and will speed up the return to travel. According to the IG Asia PTE market strategist in Singapore, Jun Rong Yep, the medicine “instills some hope that the re-opening of the economies will go smoothly, especially if the tablet can reduce the load on the hospital.” Pfizer shares on November 5 during the trading rose by 10 percent.
The cost of shares of other manufacturers of vaccines and drugs, on the contrary, decreased. On November 5, the stock shares of Biontech fell 21 percent, Moderna – by 16.6 percent, Novavax – by 11.3 percent, MERCK is 10 percent, according to NASDAQ Exchange. Securities of Chinese producers of drugs also collapsed. Shares of Cansino Biologics fell 17 percent, Wuxi Biologics Cayman producing ingredients for the Astrazeneca vaccine is 8.6 percent. Strategist CMB International Securities Daniel CO believes that the Pfizer tablet in the case of success will create uncertainty regarding forecasts of the profit of Chinese vaccine manufacturers.
In October, Merck presented its tablets from Coronavirus. According to clinical trials, the medicine has doubled the likelihood of hospitalization during coronavirus, and also reduced the risk of mortality. Currently, the company expects drug regulators to regulate the drug.